BIOCOM for BIOCOM
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocated for passage of FDA User Fee legislation Advocated against CMS National Coverage Decision on Amyloid-directed Monoclonal Antibodies for the Treatment of Alzheimers Disease Advocated for legislation that would support greater use of genetic sequencing technologies Advocated for increased utilization and uptake of digital health technologies in health care Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Held a Roundtable with Rep. Lou Correa on health issues, including new drugs and manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE New | — |
Copyright/Patent/Trademark CPT
Advocated for the protection of Intellectual Property rights Advocated for protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement. Hosted USPTO Acting Director for Silicon Valley, Steve Koziol, for a meeting about patent applications and IP issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE New | — |
Taxation/Internal Revenue Code TAX
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to protect the orphan drug tax credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Trade (domestic/foreign) TRD
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE New | — |
Budget/Appropriations BUD
Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations, including CBER Advocated for increased discretionary funding for the VA appropriations, including the National Pharmacogenomic Program Advocated for increased discretionary funding for all federally funded scientific research institutions
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK New | — |
| RICHARD WHITE | — |
Small Business SMB
Advocated for reauthorization of the SBIR/STTR Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| RICHARD WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.